A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

The abnormal activation of epidermal growth factor receptor (EGFR) drives the development of non-small cell lung cancer (NSCLC). The EGFR-targeting tyrosine kinase inhibitor osimertinib is frequently used to clinically treat NSCLC and exhibits marked efficacy in patients with NSCLC who have an EGFR...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Bin Xu, Fanjun Zeng, Jialong Deng, Lintong Yao, Shengbo Liu, Hengliang Hou, Yucheng Huang, Hongyuan Zhu, Shaowei Wu, Qiaxuan Li, Weijie Zhan, Hongrui Qiu, Huili Wang, Yundong Li, Xianzhu Yang, Ziyang Cao, Yu Zhang, Haiyu Zhou
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	KeAi Communications Co., Ltd. 2023-09-01
Seri Bilgileri:	Bioactive Materials
Konular:	Biomimetic nanoparticles Membrane targeting EGFR mutation Tyrosine kinase inhibitor Intracellular drug delivery Clinical efficacy
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2452199X23001238
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

Benzer Materyaller